84,898 results match your criteria Lupus Erythematosus Subacute Cutaneous


Alpha 1 Antitrypsin Gene Therapy Extends the Lifespan of Lupus-Prone Mice.

Mol Ther Methods Clin Dev 2018 Dec 18;11:131-142. Epub 2018 Oct 18.

Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.

Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by high levels of pathogenic autoantibodies and tissue damage. Multiple studies showed that dendritic cell (DC) activation plays a critical role in SLE pathogenesis. Human alpha 1 antitrypsin (hAAT) is a serine proteinase inhibitor with potent anti-inflammatory and cytoprotective properties. Read More

View Article
December 2018

Analysis of serum macrophage migration inhibitory factor and D-dopachrome tautomerase in systemic sclerosis.

Clin Transl Immunology 2018 6;7(12):e1042. Epub 2018 Dec 6.

Centre for Inflammatory Diseases School of Clinical Sciences at Monash Health Monash University Clayton VIC Australia.

Objectives: Macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (DDT), members of the same cytokine superfamily, are linked to the pathogenesis of a number of inflammatory diseases. The aim of this study was to investigate their clinical relevance in systemic sclerosis (SSc).

Methods: Serum MIF and DDT were quantified in 105 SSc patients by ELISA and levels compared to healthy controls (HC) (47) and patients with systemic lupus erythematosus (SLE) (184). Read More

View Article
December 2018

Postpartum flare up of systemic lupus erythematosus: Pulmonary diffused alveolar hemorrhage.

Taiwan J Obstet Gynecol 2018 Dec;57(6):906-907

Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Obstetrics and Gynecology, National Yang-Ming University School of Medicine, Taipei, Taiwan; Department of Medical Research, China Medical University Hospital, Taichung, Taiwan. Electronic address:

View Article
December 2018

The Impact of Protein Acetylation/Deacetylation on Systemic Lupus Erythematosus.

Int J Mol Sci 2018 Dec 12;19(12). Epub 2018 Dec 12.

Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA 24060, USA.

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease in which the body's immune system mistakenly attacks healthy cells. Although the exact cause of SLE has not been identified, it is clear that both genetics and environmental factors trigger the disease. Identical twins have a 24% chance of getting lupus disease if the other one is affected. Read More

View Article
December 2018
1 Read

Neurological and Inflammatory Manifestations in Sjögren's Syndrome: The Role of the Kynurenine Metabolic Pathway.

Int J Mol Sci 2018 Dec 8;19(12). Epub 2018 Dec 8.

Ribeirao Preto Medical School, Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP 14049-900 Brazil.

For decades, neurological, psychological, and cognitive alterations, as well as other glandular manifestations (EGM), have been described and are being considered to be part of Sjögren's syndrome (SS). Dry eye and dry mouth are major findings in SS. The lacrimal glands (LG), ocular surface (OS), and salivary glands (SG) are linked to the central nervous system (CNS) at the brainstem and hippocampus. Read More

View Article
December 2018

Relapsing Evans syndrome and systemic lupus erythematosus with antiphospholipid syndrome treated with Bortezomib in combination with plasma exchange.

Clin Immunol 2018 Dec 10. Epub 2018 Dec 10.

Laboratory of the Mosaics of Autoimmunity, Saint-Petersburg University, 7/9 Universitetskaya Emb., Saint- Petersburg 199034, Russia.

Relapsing Evans syndrome (ES) and systemic lupus erythematosus (SLE) with secondary antiphospholipid syndrome (APS) is very rare association. Coexistence of these syndromes is potentially fatal and require high-dose combined immunosuppressive therapy. We describe a case of successful use of Bortezomib and plasma exchange in a patient with ES and APS refractory to standard therapy. Read More

View Article
December 2018

T cell receptor revision and immune repertoire changes in autoimmune diseases.

Clin Immunol 2018 Dec 10. Epub 2018 Dec 10.

Department of Endocrinology, Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai 201318, China. Electronic address:

Autoimmune disease (AID) is a condition in which the immune system breaks down and starts to attack the body. Some common AIDs include rheumatoid arthritis, systemic lupus erythematosus, type 1 diabetes mellitus and so forth. The changes in T-cell receptor (TCR) repertoire have been found in several autoimmune diseases, and may be responsible for the breakdown of peripheral immune tolerance. Read More

View Article
December 2018

Correlation between active disease and hypercoagulability state in patients with systemic lupus erythematosus.

Clin Chim Acta 2018 Dec 10. Epub 2018 Dec 10.

Department of Clinical and Toxicological Analysis, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil. Electronic address:

Objective: This study has investigated whether high levels of Reticulocytes-C4d (R-C4d) and Platelets-C4d (P-C4d) reflecting recent activity in SLE patients are correlated with changes in natural anticoagulation components, coagulation activation and endothelial injury markers.

Methods: This study included three groups: 1) healthy women (control, n = 30); 2) women with low activity of the disease (SLEDAI 2 K ≤ 4, n = 30); 3) women with active disease (moderate or high activity) (SLEDAI 2 K > 4, n = 30). Median fluorescence intensity (MFI) of R-C4d and P-C4d were determined by flow cytometry using double labeling with specific monoclonal antibodies. Read More

View Article
December 2018

The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome.

Front Pediatr 2018 27;6:362. Epub 2018 Nov 27.

Department of Rheumatology, University College London, London, United Kingdom.

Antiphospholipid syndrome (APS) is a rare autoimmune disease of unknown etiology that represents a leading cause of acquired thromboembolism and recurrent miscarriage. It is characterized by the persistent elevated presence of pathogenic antiphospholipid auto-antibodies directed against cardiolipin, ß2-glycoprotein-I, and/or a positive lupus anticoagulant test. As with many autoimmune disorders, the pathogenesis of APS is believed to be the result of a complex interaction between environmental triggers and genetic predisposition. Read More

View Article
November 2018

Deficiency of β-Arrestin 2 in Dendritic Cells Contributes to Autoimmune Diseases.

J Immunol 2018 Dec 12. Epub 2018 Dec 12.

Putuo District People's Hospital, Shanghai Key Laboratory of Signaling and Disease Research, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China;

Altered migration and immune responses of dendritic cells (DCs) lead to inflammatory and autoimmune diseases. Our studies demonstrated that β-arrestin 2 deficiency promoted migration and cytokine production of mouse bone marrow-derived DCs. We further found that β-arrestin 2 directly interacted with Zbtb46, a DC-specific transcription factor. Read More

View Article
December 2018

SLE dacryoadenitis.

Orbit 2018 Dec 12:1-4. Epub 2018 Dec 12.

a Department of Ophthalmology , Christchurch Hospital , Christchurch , New Zealand.

In systemic lupus erythematosus, ophthalmic manifestations are noted in up to one-third of patients. We describe a patient with an unusual initial presentation of this disorder. Read More

View Article
December 2018

Overlap Syndrome-Systemic Sclerosis, Systemic Lupus Erythematosus and Dermatomyositis - Case Report.

Curr Health Sci J 2015 Jul-Sep;41(3):269-273. Epub 2015 Mar 15.

4University of Medicine and Pharmacy of Craiova, Rheumatology Department.

Overlap syndrome is often defined as an entity that satisfies the classification criteria for at least two distinct connective tissue disease. We present the case of a female patient, 39 years old, hospitalized in the Dermatology clinic of Emergency County Hospital in september 2014, for ulcerative lesions on the left hallux and the second and third left toes, associated with pain and difficulties in walking. After performing the clinical exam and paraclinical tests, we decided for both intravenous synthetic analogue of prostacyclin PGI2-iloprost and local therapeutic measures, with a favourable outcome of the ulcerations. Read More

View Article

Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab.

Front Immunol 2018 20;9:2698. Epub 2018 Nov 20.

Department of Biochemistry, University of Lausanne, Lausanne, Switzerland.

B cell activating factor of the TNF family (BAFF, also known as BLyS), a cytokine that regulates homeostasis of peripheral B cells, is elevated in the circulation of patients with autoimmune diseases such as systemic lupus erythematosus (SLE). BAFF is synthetized as a membrane-bound protein that can be processed to a soluble form after cleavage at a furin consensus sequence, a site that in principle can be recognized by any of the several proteases of the pro-protein convertase family. Belimumab is a human antibody approved for the treatment of SLE, often cited as specific for the soluble form of BAFF. Read More

View Article
November 2018

Novel Treatments in Lupus.

Front Immunol 2018 16;9:2658. Epub 2018 Nov 16.

Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.

Purpose Of Review: The standard treatment options for systemic lupus erythematosus (SLE) are focused on non-specific immunosuppression. Over the past few years, scientific studies and ongoing clinical trials have shifted the paradigm with rapid advances in developing biologics and small molecules. A number of monoclonal antibodies and small molecule inhibitors have been developed to target specific pathways involved in SLE. Read More

View Article
November 2018

Presence of Immune Complexes of IgG/IgM Bound to B2-glycoprotein I Is Associated With Non-criteria Clinical Manifestations in Patients With Antiphospholipid Syndrome.

Front Immunol 2018 20;9:2644. Epub 2018 Nov 20.

Immunology Department, Hospital 12 de Octubre, Madrid, Spain.

Antiphospholipid syndrome (APS) is an acquired autoimmune disorder defined by the presence of both clinical (thromboembolic events or pregnancy morbidity) and laboratory (antiphospholipid antibodies, aPL) manifestations. Despite their importance, several clinical manifestations strongly associated with APS such as livedo reticularis (LR), thrombocytopenia, sicca-ophthalmic(sicca), heart, or neurological manifestations are not included in the APS clinical classification criteria. Circulating immune complexes (CIC) formed by Beta-2-glycoprotein I (B2GPI) and aPL (B2-CIC) have been described and their presence has been related with thrombotic events. Read More

View Article
November 2018

Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre.

Clin Rheumatol 2018 Dec 6. Epub 2018 Dec 6.

Department of Rheumatology, Institute of Post Graduate Medical Education and Research, 240 AJC Bose Road, Kolkata, West Bengal, India.

Objective: Whether maintaining steroid-free remission is feasible in Indian patients with systemic lupus erythematosus (SLE).

Methods: In 148 patients with SLE including 78 lupus nephritis (LN) previously put into remission, steroid therapy was gradually tapered off.

Results: Patients received glucocorticoids for median 1855 days (interquartile range (IQR) 901-2834) before discontinuing. Read More

View Article
December 2018

Metabolic fingerprinting for diagnosis of fibromyalgia and other rheumatologic disorders.

J Biol Chem 2018 Dec 6. Epub 2018 Dec 6.

The Ohio State University, Food Science and Technology, United States.

Diagnosis and treatment of Fibromyalgia (FM) remains a challenge owing to the lack of reliable biomarkers. Our objective was to develop a rapid biomarker-based method for diagnosing FM by using vibrational spectroscopy to differentiate patients with FM from those with Rheumatoid Arthritis (RA), Osteoarthritis (OA) or Systemic Lupus Erythematosus (SLE), and to identify metabolites associated with these differences. Blood samples were collected from patients with a diagnosis of FM (n=50), RA (n=29), OA (n=19), or SLE (n=23). Read More

View Article
December 2018

Coexistence of Systemic Lupus Erythematosus and Myasthenia Gravis: An Unusual Case of Polyautoimmunity.

Reumatol Clin 2018 Dec 3. Epub 2018 Dec 3.

Unidad de Reumatología, Hospital Universitario San Ignacio, Bogotá, Colombia.

The relevance of polyautoimmunity, defined as the presence of 2or more autoimmune diseases in the same individual, is one of the issues not yet elucidated in medical practice. The coexistence of myasthenia gravis (MG) and systemic lupus erythematosus (SLE) is a clinical challenge due to the possible differential diagnoses of muscle involvement in patients with SLE. We present the case of a patient who came to the emergency room of Hospital Universitario San Ignacio in Bogotá, Colombia, with a previous diagnosis of SLE, who developed acute weakness in the context of a systemic infection, with a clinical and electrophysiological diagnosis of MG. Read More

View Article
December 2018

Effectiveness and Safety of Rituximab in Systemic Lupus Erythematosus: A Case Series Describing the Experience of 2 Centers.

Reumatol Clin 2018 Dec 3. Epub 2018 Dec 3.

Servicio de Reumatología, Hospital del Mar/Parc de Salut-Mar/IMIM, Barcelona, España.

Background: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs and systems. B cells have a critical role in the pathogenesis of SLE. Rituximab (RTX) is a drug composed of chimeric monoclonal antibodies against the CD20 protein, producing a depletion of B lymphocytes. Read More

View Article
December 2018

[Thrombophilia in systemic lupus erythematosus: A case-control study].

J Med Vasc 2018 Dec 31;43(6):347-353. Epub 2018 Oct 31.

Service de médecine interne, CHU la Rabta de Tunis, rue Jbel Lakhdar,La Rabta Jebbari, 1007 Tunis, Tunisie.

Introduction: To investigate the thrombotic tendency in patients with systemic lupus erythematosus (SLE) by evaluating congenital and acquired abnormalities with an increased risk of thrombosis.

Patients And Methods: A total of 53 patients with SLE were included in the study. Fifty-three healthy controls paired by age and sex were assessed. Read More

View Article
December 2018

CD84 cell surface signaling molecule: An emerging biomarker and target for cancer and autoimmune disorders.

Clin Immunol 2018 Oct 26. Epub 2018 Oct 26.

Immunology Unit, Department of Biomedical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

CD84 (SLAMF5) is a member of the SLAM family of cell-surface immunoreceptors. Broadly expressed on most immune cell subsets, CD84 functions as a homophilic adhesion molecule, whose signaling can activate or inhibit leukocyte function depending on the cell type and its stage of activation or differentiation. CD84-mediated signaling regulates diverse immunological processes, including T cell cytokine secretion, natural killer cell cytotoxicity, monocyte activation, autophagy, cognate T:B interactions, and B cell tolerance at the germinal center checkpoint. Read More

View Article
October 2018

The risks of cancer development in systemic lupus erythematosus (SLE) patients: a systematic review and meta-analysis.

Arthritis Res Ther 2018 Dec 6;20(1):270. Epub 2018 Dec 6.

Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, No. 300 Guangzhou Road, Nanjing, 210029, China.

Background: Although accumulating data have suggested the development of cancer in systemic lupus erythematosus (SLE) patients, these results remain inconsistent. To examine such a putative association, this analysis reports the association between SLE and the risks of 24 cancer types.

Methods: Online databases PubMed, EMBASE, and Web of Science were searched comprehensively for eligible studies, published up to 15 May 2018. Read More

View Article
December 2018

Intravitreal dexamethasone implant therapy for the treatment of cystoid macular Oedema due to hydroxychloroquine retinopathy: a case report and literature review.

BMC Ophthalmol 2018 Dec 6;18(1):310. Epub 2018 Dec 6.

Department of Ophthalmology, Hanyang University Hospital, Hanyang University College of Medicine, #17 Haengdang-dong, Seongdong-gu, Seoul, 133-792, South Korea.

Background: Cystoid macular oedema (CMO) is an uncommon complication associated with hydroxychloroquine (HCQ) retinopathy threatening central vision. We report a patient with HCQ retinopathy and CMO, for which an intravitreal dexamethasone implant was used, which led to complete resolution of oedema.

Case Presentation: A 57-year-old woman with systemic lupus erythematosus (SLE) complaining of blurred vision in both eyes was diagnosed with bilateral HCQ retinopathy and CMO based on characteristic photoreceptor defects and cystoid spaces on optical coherence tomography, hypo-autofluorescence on fundus autofluorescence, and corresponding visual field defects. Read More

View Article
December 2018

Is systemic lupus erythematosus different in urban versus rural living environment? Data from the Cretan Lupus Epidemiology and Surveillance Registry.

Lupus 2018 Dec 6:961203318816820. Epub 2018 Dec 6.

1 Rheumatology, Clinical Immunology and Allergy, University of Crete School of Medicine, Iraklio, Greece.

Background: Examining urban-rural differences can provide insights into susceptibility or modifying factors of complex diseases, yet limited data exist on systemic lupus erythematosus (SLE).

Objective: To study SLE risk, manifestations and severity in relation to urban versus rural residence.

Methodology: Cross-sectional analysis of the Crete Lupus Registry. Read More

View Article
December 2018

Provider perceptions on the management of lupus during pregnancy: barriers to improved care.

Lupus 2018 Dec 6:961203318815594. Epub 2018 Dec 6.

3 Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA; Duke-Margolis Center for Health Policy, Duke University, Durham, North Carolina, USA.

Background: More than half of pregnancies in women with systemic lupus erythematosus (lupus) result in adverse outcomes for the mother or the fetus. We sought to identify aspects of current rheumatologic care that could be improved to decrease the frequency of poor outcomes.

Methods: Focus groups with clinical rheumatologists, based on the PRECEDE/PROCEED framework, identified factors that influenced care. Read More

View Article
December 2018

Comment on: Adherence to hydroxychloroquine improves long-term survival of patients with systemic lupus erythematosus.

Rheumatology (Oxford) 2018 Dec 11. Epub 2018 Dec 11.

Department of Internal Medicine, Tenon Hospital (AP-HP), Paris, France.

View Article
December 2018

Neutrophils in lupus nephritis.

Curr Opin Rheumatol 2018 Dec 11. Epub 2018 Dec 11.

Center for Excellence in Vascular Biology, Department of Pathology, Brigham and Women's Hospital & Harvard Medical School, Boston, USA.

Purpose Of Review: Systemic lupus erythematosus (SLE) is a multiorgan autoimmune disease characterized by IgG-autoantibodies to nuclear antigens that can deposit in the kidney and trigger lupus nephritis. Neutrophils accumulate in the kidneys of patients with proliferative LUPUS NEPHRITIS and neutrophil products and a subset of granulocytes, called low-density granulocytes (LDG) may contribute to lupus nephritis pathogenesis. Here, we will discuss recent studies implicating neutrophils in the pathogenesis of human SLE nephritis and then examine studies that provide mechanistic insights into how these cells are recruited to the glomerulus following immune complex deposition and how their products may promote lupus nephritis. Read More

View Article
December 2018

Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations.

Curr Opin Rheumatol 2018 Dec 11. Epub 2018 Dec 11.

Department of Medicine/Rheumatology and Clinical Immunology.

Purpose Of Review: This review summarizes recent insights and current understanding of the role of postactivated B cells in SLE and related pathogenic and potential therapeutic implications.

Recent Finding: B cells are considered key players in SLE and experience from various B-cell-targeted therapies underlines their clinical relevance. In the last years, new insights have been obtained on B-cell abnormality within the complex pathophysiology of SLE. Read More

View Article
December 2018

Gene-function studies in SLE.

Curr Opin Rheumatol 2018 Dec 11. Epub 2018 Dec 11.

Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán.

Purpose Of Review: The aim of this review is to discuss recent developments in our understanding of how systemic lupus erythematosus (SLE)-associated genes contribute to autoimmunity.

Recent Findings: Gene-function studies have revealed mechanisms through which SLE-associated alleles of IFIH1, TNFAIP3, IRF5, and PRDM1 likely contribute to the development of autoimmunity. Novel research has identified Mac-1 (encoded by ITGAM), CaMK4, and iRhom2 as plausible therapeutic targets in lupus nephritis. Read More

View Article
December 2018
1 Read

rs2217560 was Associated with Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus.

Chin Med J (Engl) 2018 Dec;131(24):3020-3021

Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China.

View Article
December 2018

Alcohol intake and risk of systemic lupus erythematosus: a Mendelian randomization study.

Authors:
S C Bae Y H Lee

Lupus 2018 Dec 12:961203318817832. Epub 2018 Dec 12.

2 Department of Rheumatology, Korea University College of Medicine, Seoul, Korea.

Objectives: This study aimed to examine whether alcohol intake is causally associated with systemic lupus erythematosus (SLE).

Methods: We performed a two-sample Mendelian randomization (MR) analysis using the inverse-variance weighted (IVW), weighted median, and MR-Egger regression methods. We used the publicly available summary statistics of alcohol intake frequency from the UK Biobank genome-wide association studies (GWASs; n = 336,965) as the exposure and an SLE GWAS consisting of 1311 SLE and 1783 control subjects of European descent as the outcome. Read More

View Article
December 2018

Detection of Autoantibodies to Complement Components by Surface Plasmon Resonance-Based Technology.

Methods Mol Biol 2019 ;1901:271-280

INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, Paris, France.

The innate immune complement system is a powerful defense cascade against pathogens, but can induce host tissue damage when overactivated. In pathological conditions, mainly but not restricted to renal diseases, such as lupus nephritis, atypical hemolytic uremic syndrome, and C3 glomerulopathies, complement is overactivated or dysregulated by autoantibodies directed against its components and regulators. Among the key autoantibody targets are the initiator of the classical complement pathway C1q, the alternative pathway regulator Factor H, the components of the alternative pathway C3 convertase complex C3 and Factor B and the convertase complex itself. Read More

View Article
January 2019

Determination of CRP Autoantibodies by SPR Immunoassay.

Methods Mol Biol 2019 ;1901:205-219

MOE Key Laboratory of Environment and Genes Related to Diseases, School of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shanxi, People's Republic of China.

Biosensors based on the principle of surface plasmon resonance (SPR) are surface-sensitive optical devices used for monitoring biomolecular interactions at the sensor surface in real time without any labeling. It is used in a wide variety of areas including proteomics, clinical diagnosis, environmental monitoring, drug discovery, and food analysis. C-reactive protein (CRP) is a marker of inflammation, which undergoes conformation changes in local lesions, leading to the formation of mCRP. Read More

View Article
January 2019

Analysis of Anti-C1q Autoantibodies by Western Blot.

Methods Mol Biol 2019 ;1901:183-189

Clinical Immunology and Transfusion Medicine, Region Skåne, Sweden.

Anti-C1q autoantibodies may be found in many conditions, most commonly in systemic lupus erythematosus (SLE) and hypocomplementemic urticarial vasculitis syndrome (HUVS), and are diagnostic markers as well as disease activity markers in lupus nephritis. Sera from patients with SLE and HUVS show partly distinct autoantibody reactivities to separated protein chains B and C of the first component of complement, C1q. These different binding specificities can be detected by Western blot analysis of the autoantibodies under reducing conditions. Read More

View Article
January 2019

Detection of DNA Autoantibodies by Electrophoretic Mobility Shift Assay.

Methods Mol Biol 2019 ;1901:133-152

Laboratory for Life Sciences, Tehran, Iran.

Although the presence of antibodies against double-stranded (ds) DNA is considered the serological hallmark of systemic lupus erythematosus (SLE), it is not detected in all SLE patients by routine laboratory tests. Looking at DNA-anti(ds)DNA interaction as one kind of DNA-protein interaction gave us the grounds for a novel type of assay, easy to perform, and providing a direct insight on DNA-anti(ds)DNA IgG interaction. The assay is an application of the electrophoretic mobility shift assay (EMSA) and is based on the observation that the electrophoretic mobility of a DNA-protein complex is typically less than that of free DNA. Read More

View Article
January 2019

An Efficient Method to Generate Monoclonal Antibodies from Human B Cells.

Methods Mol Biol 2019 ;1904:109-145

Department of Medicine, Section of Rheumatology, The Knapp Center for Lupus and Immunology, University of Chicago, Chicago, IL, USA.

In the age of personalized medicine, an efficient method to generate monoclonal antibodies (mAbs) is essential for biomedical and immunotherapeutic research. Numerous aspects of basic B-cell biology can be studied at the monoclonal level, including B-cell development, antibody responses to infection or vaccination, and autoimmune responses. Single-cell B-cell receptor cloning allows for the rapid generation of antigen-specific mAbs in a matter of several weeks. Read More

View Article
January 2019

Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort.

Clin Rheumatol 2018 Dec 12. Epub 2018 Dec 12.

Rheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen - EsSalud, Lima, Peru.

Objective: To determine the impact of homocysteine levels on damage accrual in systemic lupus erythematosus (SLE) patients.

Methods: This longitudinal study was conducted in consecutive patients seen every 6 months at our Rheumatology Department since 2012. Patients with available homocysteine levels and who had at least one subsequent visit were included. Read More

View Article
December 2018

Habitat use of sympatric prey suggests divergent anti-predator responses to recolonizing gray wolves.

Oecologia 2018 Dec 11. Epub 2018 Dec 11.

School of Environmental and Forest Sciences, University of Washington, Seattle, WA, USA.

The non-consumptive effects of predators on prey are now widely recognized, but the need remains for studies identifying the factors that determine how particular prey species respond behaviorally when threatened with predation. We took advantage of ongoing gray wolf (Canis lupus) recolonization in eastern Washington, USA, to contrast habitat use of two sympatric prey species-mule (Odocoileus hemionus) and white-tailed (O. virginianus) deer-at sites with and without established wolf packs. Read More

View Article
December 2018

An Unusual Presentation of Lupus Vulgaris and the Practical Usefulness of Dermatoscopy.

Case Rep Dermatol Med 2018 14;2018:1036162. Epub 2018 Nov 14.

Specialist in Dermatology-Venereology, Chief of State Clinic of Dermatology, Hospital for Skin and Venereal Diseases, Delfon 124, 54643 Thessaloniki, Greece.

We report a case report of lupus vulgaris (LV) presented on the extremities of an 80-year-old man. He was misdiagnosed as having psoriasis and referred to our department for a second-opinion evaluation. The discrepancy between the clinical manifestation which was misleading and the dermatoscopic findings raised the suspicion of an underlying granulomatous disease and we proceeded to skin biopsy. Read More

View Article
November 2018
1 Read

Antibodies to and reproductive health issues in women with SLE: a case-control study.

Lupus Sci Med 2018 21;5(1):e000293. Epub 2018 Nov 21.

Department of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland.

Background: SLE is an autoimmune condition affecting predominantly women. Little is known regarding infection in women with SLE, which may drive autoimmunity and contribute to obstetrical and vascular complications.

Methods: This single-centre, case-control study set primary endpoint in the comparative seropositivity rate to major outer membrane protein (MOMP) and chlamydial heat-shock protein-60 (cHSP60) in age-matched subjects. Read More

View Article
November 2018
1 Read

Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort.

Lupus Sci Med 2018 2;5(1):e000287. Epub 2018 Nov 2.

Division of Rheumatology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Objectives: The aim of this study is to identify prognostic factors of persistent disease activity and long quiescence in systemic lupus erythematosus (SLE).

Methods: Patients enrolled in the Hopkins Lupus Cohort from 1987 to 2012, who attended at least three visits per year during 3 consecutive years following baseline and had available information on disease activity were included. Patterns of SLE disease activity over the 3-year period were defined as: persistent long quiescent (pLQ), persistent relapsing-remitting (pRR), persistent chronic active (pCA) and mixed based on Modified SLE Disease Activity Index (M-SLEDAI). Read More

View Article
November 2018

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE.

Lupus Sci Med 2018 22;5(1):e000286. Epub 2018 Nov 22.

Research Bioinformatics, MedImmune LLC, Gaithersburg, Maryland, USA.

Objective: Anifrolumab is a fully human immunoglobulin G κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe SLE, anifrolumab treatment demonstrated substantial reductions in multiple clinical endpoints. Here, we evaluated serum proteins and immune cells associated with SLE pathogenesis, type I interferon gene signature (IFNGS) test status and disease activity, and how anifrolumab affected these components. Read More

View Article
November 2018

Validation of the Cutaneous Lupus Erythematosus Disease Area and Severity Index and pSkindex27 for use in childhood-onset systemic lupus erythematosus.

Lupus Sci Med 2018 17;5(1):e000275. Epub 2018 Nov 17.

Department of Pediatrics, University of Cincinnati College of Medicine, Division of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

Objective: To determine the measurement properties of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) and the paediatric adaptation of the Skindex29 (pSkindex27) when used in childhood-onset SLE (cSLE).

Methods: Patients with mucocutaneous involvement of cSLE were evaluated at the study entry and 6 months later. Besides the CLASI and pSkindex27, the Pediatric Quality of Life Inventory Generic Core scale (PedsQL-GC), its Rheumatology Module (PedsQL-RM), the SLE Disease Activity Index (SLEDAI) and the SLE Damage Index (SDI) were completed. Read More

View Article
November 2018
1 Read

Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres.

Lupus Sci Med 2018 2;5(1):e000274. Epub 2018 Nov 2.

Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy.

Objectives: To analyse the real-life practice on the use of Tacrolimus (TAC) in patients with systemic lupus erythematosus (SLE) from three European SLE referral centres.

Methods: Adult patients with SLE regularly followed at three European referral centres were included. Demographics, cumulative organ involvement, treatment history, Systemic Lupus Disease Activity Index (SLEDAI), laboratory features and physician's judgement were collected at baseline and at 3-6-12 months after starting TAC. Read More

View Article
November 2018
1 Read

Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors.

Lupus Sci Med 2018 17;5(1):e000267. Epub 2018 Nov 17.

Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Faculty of Biology Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

Objectives: We aimed to describe the rate and determinants of carotid plaque progression and the onset of clinical cardiovascular disease (CVD) in a UK SLE cohort.

Methods: Female patients with SLE of white British ancestry were recruited from clinics in the North-West of England and had a baseline clinical and CVD risk assessment including measurement of carotid intima-media thickness (CIMT) and plaque using B-mode Doppler ultrasound. Patients were followed up (>3. Read More

View Article
November 2018

Subcutaneous formulation of belimumab in treatment of systemic lupus erythematosus: a critical review with focus on safety and satisfaction.

Patient Prefer Adherence 2018 21;12:2475-2479. Epub 2018 Nov 21.

Internal Medicine Department, Rochester General Hospital, Rochester, NY, USA,

Belimumab is a novel add-on therapy that has been approved for patients with active and antibody-mediated systemic lupus erythematosus. It is a monoclonal antibody that decreases the activation of B-cells and consequently decreases antibodies' production. Recently, the US Food and Drug Administration approved subcutaneous belimumab for patients who have received training on using it. Read More

View Article
November 2018

New therapeutic strategies in systemic lupus erythematosus management.

Nat Rev Rheumatol 2018 Dec 11. Epub 2018 Dec 11.

Unit of Rheumatology, Department of Medicine, University of Padova, Padova, Italy.

The current treatment approach for systemic lupus erythematosus (SLE), as outlined in the recommendations by international medical associations including EULAR and the ACR, is mostly eminence-based rather than evidence-based. However, knowledge on SLE is growing quickly, and such new advances need to be translated into clinical practice. Questions remain regarding the choice and timing of drug administration and tapering until withdrawal, which both can affect the balance between the control of disease activity and damage to organs triggered by long-standing and/or disproportionate immunosuppression. Read More

View Article
December 2018

Sex Hormones and Prolactin Levels and Their Association with Anti Cardiolipin Antibody in Patients with Systemic Lupus Erythematosus.

Iran J Allergy Asthma Immunol 2018 Aug 12;17(4):336-345. Epub 2018 Aug 12.

Department of Internal Medicine, Lorestan University of Medical Sciences, khorramabad, Iran.

Pathogenesis of systemic lupus erythematosus (SLE) is complex and multi-factorial. Among various suggested mechanisms for the disease, the hormonal theory has been considered as one of the most important mechanisms. Recently, the association of sex hormones with manifestations of antiphospholipid antibody syndrome (APLS) has been hypothesized. Read More

View Article

Better Biomarkers for Lupus Disease Activity - Tools for Treating to Target.

Authors:
Susan A Boackle

Arthritis Rheumatol 2018 Dec 7. Epub 2018 Dec 7.

Division of Rheumatology, University of Colorado Denver School of Medicine, Aurora, CO.

Sometimes new ideas come from old places. Complement's central role in lupus pathogenesis has been known for years, and a reduction in C3 and C4 levels is one of the strongest biomarkers for increased lupus disease activity. However, every rheumatologist knows that some patients with no symptoms of active lupus will present with low complement levels, whereas some patients with aggressive disease have levels that never budge from the "normal" range. Read More

View Article
December 2018

HMGB1+ microparticles present in urine are hallmarks of nephritis in patients with systemic lupus erythematosus.

Eur J Immunol 2018 Dec 10. Epub 2018 Dec 10.

Grupo de Inmunología Celular e Inmunogenética, Instituto de Investigaciones Médicas, Facultad de Medicina, Universidad de Antioquia UdeA, Calle 70 No 52-21, Medellín, Colombia.

Non-classical monocytes infiltrate the kidney parenchyma and participate in tissue damage in patients with lupus nephritis (LN). Circulating microparticles (MPs) seem to play critical roles in the activation of monocytes in systemic lupus erythematosus (SLE) patients. This study aims to characterize the phenotypes of MPs and monocyte subsets in LN patients and to determine their potential to discriminate between SLE patients with and without LN. Read More

View Article
December 2018
1 Read